Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

@inproceedings{Liu2017InhibitingTS,
  title={Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation},
  author={David H. Liu and Cuong Phu Duong and Sue Haupt and Karen G. Montgomery and Colin House and Walid J. Azar and Helen B. Pearson and Oliver Maximilian Fisher and Matthew Read and Glen R Guerra and Ygal Haupt and Carleen Cullinane and Klas G Wiman and Lars Abrahms{\'e}n and Wayne A Phillips and Nicholas James Clemons},
  booktitle={Nature communications},
  year={2017}
}
TP53, a critical tumour suppressor gene, is mutated in over half of all cancers resulting in mutant-p53 protein accumulation and poor patient survival. Therapeutic strategies to target mutant-p53 cancers are urgently needed. We show that accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine/glutamate antiporter, system xC-, through binding to the master antioxidant transcription factor NRF2. This diminishes glutathione synthesis, rendering mutant-p53… CONTINUE READING